

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MURRAY & POOLE ENTERPRISES, LTD.,
Petitioner,
v.

INSTITUT DE CARDIOLOGIE DE MONTREAL,
Patent Owner,

Case IPR2023-01064
Patent No. 11,400,063

DECLARATION OF NADIA BOUABDALLAOUI, M.D., Ph.D

1. I, Nadia Bouabdallaoui, M.D., Ph.D., submit this declaration in the above-referenced proceeding. I have personal knowledge of everything outlined in this declaration unless specifically noted otherwise.

2. I am a co-author of Bouabdallaoui et al. “Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT),” Eur. Heart J. (2020) 41, 4092–4099 (“Bouabdallaoui,” EX1005). Bouabdallaoui et al. is a sub-analysis of the data obtained in a clinical investigation called the Colchicine Cardiovascular Outcomes Trial study, also known as the “COLCOT” study.

3. I did not develop the COLCOT study hypothesis and was not involved in conducting the main study. Along with the other listed co-authors, I worked on a secondary analysis of the study's results and participated in the writing of the article by Bouabdallaoui et al.

4. I do not consider myself an inventor of U.S. Patent No. 11,400,063 (“the ’063 patent”) (EX1001).

5. I am not being separately compensated for this declaration.

I. PERSONAL BACKGROUND

6. I am a medical doctor who has focused my practice on treating patients with cardiovascular issues since 2009. I was trained in France and am now practicing in Canada.

7. I am currently employed at the Institut de Cardiologie de Montréal, which I will refer to as the “Montreal Heart Institute” or “MHI.” In June 2019, I became a faculty member at MHI, where my focus is clinical management of patients with heart disease.

II. BOUABDALLAOUI ET AL. ARTICLE


8. I have known Dr. Tardif since approximately 2018. In 2020, he approached me to participate in authoring the article by Bouabdallaoui et al., which further analyzes results from the COLCOT study.

9. The article by Bouabdallaoui et al., published in the European Heart Journal (2020), presents a sub-analysis derived from the COLCOT study. This analysis compares patients included in the COLCOT study based on the timing of treatment initiation (colchicine or placebo) following myocardial infarction. Notably, patients whose medication was initiated early after experiencing a myocardial infarction demonstrated improved outcomes.

10. While I am the first named author of the Bouabdallaoui et al. article, Dr. Tardif is the corresponding author, which in academia indicates that the individual is the senior researcher responsible for the article. The corresponding author gets the article into publication and speaks on behalf of the other co-authors to the publishers and the readers. The corresponding author is responsible for, among other things, manuscript corrections, publishing agreements, and

responding to inquiries about the article on behalf of the co-authors. Dr. Tardif asked me to be the first named author of the article because I was working under his guidance.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed this 21st day of March 2024.

A handwritten signature in black ink, reading "Nadia Bouabdallaoui". The signature is written in a cursive style with a horizontal line underneath the name.

Nadia Bouabdallaoui, M.D., Ph.D.

SHDOCS:220631764.4